Story perspectives

Zolgensma Price Crisis: Access Challenges for Children

12/15/2025

25 2

Summary

Story summary

Zolgensma's $2 million per-dose price creates access challenges for children with spinal muscular atrophy.
Maisie Green, a child patient, faced insurance denial for Zolgensma and a coverage fight.
Health economist Jonathan Gruber warns of a looming crisis as more expensive therapies enter the market.
Drug manufacturers say costs will fall with increased production and regulatory changes.
The situation calls for a collective societal response to absorb these costs.

1 of 1

Story summary

Zolgensma's $2 million per-dose price creates access challenges for children with spinal muscular atrophy.
Maisie Green, a child patient, faced insurance denial for Zolgensma and a coverage fight.
Health economist Jonathan Gruber warns of a looming crisis as more expensive therapies enter the market.
Drug manufacturers say costs will fall with increased production and regulatory changes.
The situation calls for a collective societal response to absorb these costs.